Smart liposome cosmetic composition having excellement improvement effect on state of skin

Abstract

The present invention relates to a liposome composition, a cosmetic composition comprising same as an active ingredient, and the like, the liposome composition comprising: an oil phase part comprising phospholipids; and an aqueous phase part comprising a skin-active substance, a melanocyte-targeting peptide, and a surfactant. The composition according to one aspect is characterized in that the melanocyte-targeting peptide targets target cells, including melanocytes, so as to increase the delivery efficiency of the skin-active substance, and the stability and activity of liposomes are optimized according to the combination ratio between surfactants.

Description

Smart liposome cosmetic composition with excellent efficacy in improving skin condition

[0001] The present invention relates to a liposome composition comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant, and a cosmetic composition containing the same as an active ingredient.

[0002]

[0003] Skin health and beauty are important elements of modern life, and cosmetic products aiming for improvement in various aspects—such as skin whitening, antioxidant effects, anti-aging, elasticity, hydration, and wrinkle reduction—are receiving significant attention. Consequently, the demand for maintaining healthy skin is surging, and various functional cosmetics are being researched and developed to meet this need.

[0004] Liposomes are representative biocompatible skin delivery systems primarily used in Drug Delivery Systems (DDS). They are characterized by their ability to carry both hydrophilic and hydrophobic substances, with water-soluble components solubilized in the aqueous core and lipid-soluble components in the phospholipid membrane. Liposomes can efficiently deliver active ingredients to the skin, enhancing absorption rates and facilitating delivery to deep skin layers. Consequently, they can be utilized for various skin condition improvements, including skin whitening, antioxidant effects, anti-aging, skin elasticity enhancement, hydration, and wrinkle reduction. In particular, "smart liposomes" can be designed to specifically deliver active ingredients to target cells or to target and release cosmetic ingredients based on external stimuli (e.g., pH, temperature, ion concentration, etc.).

[0005] However, despite containing various active ingredients, existing cosmetic products often fail to deliver them efficiently to the skin, or their effects are short-term due to structural instability. Against this backdrop, the inventors have developed liposomes composed of an optimal concentration to enhance the skin absorption of active substances possessing skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening activities.

[0006]

[0007] One aspect provides a liposome composition comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant.

[0008] Another aspect provides a cosmetic composition comprising the above liposome composition.

[0009] Another aspect provides a topical skin composition comprising the above liposome composition.

[0010]

[0011] One aspect provides a liposome composition comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant.

[0012] The term 'liposome' in this specification refers to a spherical or elliptical structure surrounded by a fine lipid membrane, having the form of a lipid bilayer or multilayer vesicle.

[0013] The above lipid may be an amphoteric lipid, specifically a phospholipid, and the above phospholipid may be any one selected from the group consisting of lecithin, phosphatidylcholine, phosphatidic acid, phosphatidylserine, phosphatidyl glycerol, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, plasmalogen, dicetylphosphate, distearoylphosphatidylcholine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, and any combination thereof.

[0014] Specifically, the above 'lecithin' can be naturally produced as a diglyceride mixture of stearic acid, palmitic acid, and oleic acid, and the composition of fatty acids may vary depending on the source. In one embodiment of the present invention, hydrogenated lecithin produced by controlling the hydrogenation (hydrogenation addition) of lecithin was used.

[0015] The above phospholipid may be included in the range of 0.01 to 10 parts by weight, 0.01 to 5 parts by weight, 0.01 to 3 parts by weight, 0.01 to 1 part by weight, 0.05 to 10 parts by weight, 0.05 to 5 parts by weight, 0.05 to 3 parts by weight, 0.05 to 1 part by weight, 0.05 to 10 parts by weight, 0.1 to 10 parts by weight, 0.1 to 5 parts by weight, 0.1 to 3 parts by weight, 0.1 to 1 part by weight, 0.5 to 10 parts by weight, 0.5 to 5 parts by weight, 0.5 to 3 parts by weight, 0.5 to 1 part by weight, 1 to 10 parts by weight, 1 to 5 parts by weight, and 1 to 3 parts by weight, based on 100 parts by weight of the liposome composition.

[0016] The above surfactants are polyglyceryl-6 laurate, lauryl glucoside, myristyl glucoside, polyglyceryl-10 caprylate, polyglyceryl-3 methylglucose distearate, glucolipid, risolecithin, sorbitan stearate, glyceryl oleate, glyceryl stearate, polyoxyalkylene alkyl ether, polyoxyalkylene fatty acid ester, alkyl polyglucoside, sodium lauryl ether sulfate, stearyl trimethyl ammonium chloride, alkyl polyglyceryl ether, stearyl trimethyl ammonium chloride, lauryl trimethyl ammonium chloride, distearyl dimethyl-ammonium chloride, poly(N, N′ dimethyl-3,5-methylenepiperidinium) chloride, cetylpyridinium chloride, alkyl tetraammonium salt, alkyl dimethylbenzylammonium salt, It may be one or more selected from the group consisting of alkylisoquinolinium salts, dialkyl-morpholium salts, polyamine fatty acid derivatives, amyl alcohol fatty acid derivatives, benzalkonium chloride and benzetonium chloride and potassium cetyl phosphate, and specifically, it may be one selected from the group consisting of polyglyceryl-6 laurate, lauryl glucoside, myristyl glucoside, polyglyceryl-10 caprylate and combinations thereof.

[0017] The above surfactants may each be included in an amount of 0.001 to 1 part by weight, 0.001 to 0.5 parts by weight, 0.001 to 0.3 parts by weight, 0.001 to 0.1 parts by weight, 0.005 to 1 part by weight, 0.005 to 0.5 parts by weight, 0.005 to 0.3 parts by weight, 0.005 to 0.1 parts by weight, 0.01 to 1 part by weight, 0.01 to 0.5 parts by weight, 0.01 to 0.3 parts by weight, 0.01 to 0.1 parts by weight, 0.05 to 1 part by weight, 0.05 to 0.5 parts by weight, 0.05 to 0.3 parts by weight, and 0.05 to 0.1 parts by weight, respectively, relative to 100 parts by weight of the liposome composition.

[0018] In this specification, the term 'skin active substance' may refer to any substance capable of imparting useful activity to an individual, such as skin regeneration, anti-aging, antioxidant, wrinkle improvement and elasticity enhancement, skin whitening activity, etc. Specifically, the skin active substance may be (i) an antioxidant component, (ii) an anti-inflammatory or skin soothing component, (iii) a whitening component, or (iv) a moisturizing or skin barrier strengthening component. Preferably, the antioxidant component may be a vitamin or its derivative, a polyphenol compound, or a flavonoid compound, specifically vitamin C (ascorbic acid), ascorbyl glucoside, 3-O-ethylascorbic acid, magnesium ascorbyl phosphate, tocopherol, coenzyme Q10, glutathione, carotenoids, anthocyanin, catechin, apigenin, luteolin, genistein, quercetin, curcumin, kaempferol, resveratrol, isoflavones, or flavonoids. In addition, the anti-inflammatory or skin-soothing ingredient may be a plant-derived extract, bisabolol, licorice extract, paper mulberry extract, or glycyrrhizin. The whitening ingredient may be arbutin, phenethylenesorcinol, tranexamic acid, potassium methoxyhydrosalicylate, or vitamin C and its derivatives. The moisturizing or skin barrier strengthening ingredient may be collagen or hyaluronic acid. Furthermore, the skin active substance may be one or more of the compounds mentioned above or derivatives thereof, but is not particularly limited thereto.

[0019] Depending on the type of skin active substance loaded within the liposome of the present invention, the specific efficacy of the cosmetic composition or topical skin preparation to which it is applied may vary, and the type and content of the loaded skin active substance may be appropriately selected by those skilled in the art.

[0020] The above skin active substance may be included in the range of 0.01 to 10 parts by weight, 0.01 to 5 parts by weight, 0.01 to 3 parts by weight, 0.01 to 1 part by weight, 0.05 to 10 parts by weight, 0.05 to 5 parts by weight, 0.05 to 3 parts by weight, 0.05 to 1 part by weight, 0.05 to 10 parts by weight, 0.1 to 10 parts by weight, 0.1 to 5 parts by weight, 0.1 to 3 parts by weight, 0.1 to 1 part by weight, 0.5 to 10 parts by weight, 0.5 to 5 parts by weight, 0.5 to 3 parts by weight, 0.5 to 1 part by weight, 1 to 10 parts by weight, 1 to 5 parts by weight, and 1 to 3 parts by weight, based on 100 parts by weight of the liposome composition of the present invention.

[0021] The above melanocyte target peptide may be any one selected from the group consisting of NAP represented by the amino acid sequence of SEQ ID NO. 1, LK-514 represented by the amino acid sequence of SEQ ID NO. 2, γ-MSH represented by the amino acid sequence of SEQ ID NO. 3, and combinations thereof.

[0022] Melanocyte-targeting peptides are included in a liposome composition, which allows skin-active substances included in the liposome composition to be effectively delivered to melanocytes, thereby enhancing the effect of the skin-active substances.

[0023] Specifically, the melanocyte target peptides target melanocytes and may be Ac-Nle-DHfRWGK (NAP) (SEQ No. 1); (4-phenylbutyryl)-Hf(tBu)-RK (LK-514) (SEQ No. 2); YVMGHFRWDRFK(γ-MSH) (SEQ No. 3); and combinations thereof.

[0024] The above melanocyte target peptide may be included in a range of 0.001 to 0.9 parts by weight, 0.001 to 0.5 parts by weight, 0.001 to 0.3 parts by weight, 0.001 to 0.1 parts by weight, 0.005 to 0.9 parts by weight, 0.005 to 0.5 parts by weight, 0.005 to 0.3 parts by weight, 0.005 to 0.1 parts by weight, 0.01 to 0.9 parts by weight, 0.01 to 0.5 parts by weight, 0.01 to 0.3 parts by weight, 0.01 to 0.1 parts by weight, 0.05 to 0.9 parts by weight, 0.05 to 0.5 parts by weight, 0.05 to 0.3 parts by weight, and 0.05 to 0.1 parts by weight, based on 100 parts by weight of the liposome composition.

[0025] It is preferable that the above-mentioned melanocyte target peptides NAP, LK-514, and γ-MSH are included in a weight ratio of 0.5 to 5 : 0.5 to 5 : 0.5 to 5, and specifically, in a weight ratio of 0.5 to 4 : 0.5 to 4 : 0.5 to 4; 0.5 to 3 : 0.5 to 3 : 0.5 to 3; 0.5 to 2 : 0.5 to 2 : 0.5 to 2; or 0.5 to 1.5 : 0.5 to 1.5 : 0.5 to 1.5. Additionally, the above-mentioned melanocyte target peptides may be included in a weight ratio of 0.6 to 4 : 0.6 to 4 : 0.6 to 4; 0.6 to 3 : 0.6 to 3 : 0.6 to 3; It may be included in a weight ratio of 0.6 to 2 : 0.6 to 2 : 0.6 to 2; or 0.6 to 1.5 : 0.6 to 1.5 : 0.6 to 1.5. Furthermore, the melanocyte target peptide may be included in a weight ratio of 0.7 to 4 : 0.7 to 4 : 0.7 to 4; 0.7 to 3 : 0.7 to 3 : 0.7 to 3; 0.7 to 2 : 0.7 to 2 : 0.7 to 2; or 0.7 to 1.5 : 0.7 to 1.5 : 0.7 to 1.5. Additionally, the melanocyte target peptide may be included in a weight ratio of 0.8 to 4 : 0.8 to 4 : 0.8 to 4; 0.8 to 3 : 0.8 to 3 : 0.8 to 3; It may be included in a weight ratio of 0.8 to 2 : 0.8 to 2 : 0.8 to 2; or 0.8 to 1.5 : 0.8 to 1.5 : 0.8 to 1.5. Additionally, the melanocyte target peptide may be included in a weight ratio of 0.9 to 4 : 0.9 to 4 : 0.9 to 4; 0.9 to 3 : 0.9 to 3 : 0.9 to 3; 0.9 to 2 : 0.9 to 2 : 0.9 to 2; or 0.9 to 1.5 : 0.9 to 1.5 : 0.9 to 1.5. Furthermore, the melanocyte target peptide may be included in a weight ratio of 0.95 to 4 : 0.95 to 4 : 0.It may be included in a weight ratio of 95 to 4; 0.95 to 3 : 0.95 to 3 : 0.95 to 3; 0.95 to 2 : 0.95 to 2 : 0.95 to 2; or 0.95 to 1.5 : 0.95 to 1.5 : 0.95 to 1.5, and most preferably in a weight ratio of 1 : 1 : 1.

[0026] As previously mentioned, the liposome composition comprises a melanocyte-targeting peptide, a surfactant, a skin-active substance, and a phospholipid. In this case, the liposome composition may comprise 150 to 300 parts by weight of a surfactant, 200 to 600 parts by weight of a skin-active substance, and 100 to 300 parts by weight of a phospholipid, based on 1 part by weight of a melanocyte-targeting peptide.

[0027] Preferably, the surfactant may be included in an amount of 160 to 280 parts by weight, 170 to 260 parts by weight, 180 to 240 parts by weight, 190 to 220 parts by weight, or 195 to 210 parts by weight, and most preferably 202 parts by weight. In this case, the surfactant may be polyglyceryl-6 laurate, lauryl glucoside, myristyl glucoside, polyglyceryl-10 caprylate, or a combination thereof, and when combined, the four components may be included in a weight ratio of 45 to 55 : 25 to 35 : 15 to 25 : 0.5 to 2, preferably 50 : 30 : 20 : 1.

[0028] Preferably, the skin active substance may be included in an amount of 250 to 550 parts by weight, 300 to 500 parts by weight, 350 to 450 parts by weight, 380 to 420 parts by weight, or 390 to 410 parts by weight, and most preferably 400 parts by weight. In this case, the skin active substance may be an antioxidant, such as ascorbic acid.

[0029] Preferably, the phospholipid may be included in an amount of 120 to 280 parts by weight, 140 to 260 parts by weight, 160 to 240 parts by weight, 180 to 220 parts by weight, or 190 to 210 parts by weight, and most preferably 200 parts by weight. In this case, the phospholipid may be lecithin or hydrogenated lecithin.

[0030] Most preferably, the liposome composition may comprise 202 parts by weight of a surfactant, 400 parts by weight of a skin active substance, and 200 parts by weight of a phospholipid, based on 1 part by weight of a melanocyte target peptide.

[0031] The above liposome composition may be used for delivering skin active substances to skin cells.

[0032]

[0033] Another aspect is to provide a cosmetic composition for improving skin condition comprising the above-described liposome composition. The same parts as described above also apply to the above-described cosmetic composition.

[0034] Specifically, the above 'improvement of skin condition' may mean one or more selected from the group consisting of skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening, and thus the cosmetic composition may be a cosmetic composition for skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, or skin whitening.

[0035] The term 'skin regeneration' in this specification refers to a series of reactions in which skin tissue is reorganized in response to skin aging or damage caused to the skin, and specifically, this can be carried out by the differentiation, proliferation, and migration of keratinocytes.

[0036] In this specification, the term "anti-aging" refers to any act of preventing functional degeneration due to aging of skin cells and tissues, and "antioxidant" refers to inhibiting oxidative stress and cellular oxidation caused by free radicals or reactive oxygen species induced by ultraviolet rays, etc., and may mean reducing skin cell damage caused by removing free radicals or reactive oxygen species. In this specification, the term "skin whitening" refers to making the skin white, and specifically may mean alleviating or improving various pigmentations, including melasma and freckles, caused by excessive synthesis or deposition of melanin.

[0037] In this specification, the term 'skin wrinkle improvement' refers to any action that reduces or slows down the rate of wrinkle formation caused by a decrease in collagen fibers or a decrease in the amount of collagen produced within the skin, and 'elasticity enhancement' may refer to any action that increases the elasticity and restorability of the skin due to an increase in the absorption or production of collagen within the skin.

[0038] The above cosmetic composition may be manufactured in various forms, for example, the composition may be manufactured in any one formulation selected from the group consisting of lotion (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, suspension, gel, powder, paste, mask pack or sheet, and aerosol, and the composition of such formulation may be manufactured according to methods conventional in the field. The above cosmetic composition may further include preservatives, stabilizers, surfactants, solvents, moisturizers, emollients, UV absorbers, antiseptics, disinfectants, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, cooling agents or limiting agents, etc. The amount of additional ingredients such as the above moisturizer can be easily selected by a person skilled in the art within a range that does not impair the purpose and effect of the present invention, and the amount may be 0.001 to 5 weight%, specifically 0.01 to 3 weight%, based on the total weight of the composition.

[0039]

[0040] Another aspect is to provide a topical skin composition for improving skin condition comprising the above-described liposome composition. The same parts as described above also apply to the topical skin composition.

[0041] The above-mentioned topical preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The above-mentioned topical preparation may be appropriately formulated as needed with ingredients commonly used in topical preparations for the skin, such as cosmetics or pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof.

[0042] In addition, the above external skin preparation may be appropriately formulated by a person skilled in the art with metal chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glablidin, hot water extract of the fruit of Carin, various herbal medicines, pharmaceuticals such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof; and sugars such as vitamin C, magnesium ascorbate phosphate, ascorbate glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.

[0043]

[0044] Another aspect of the present invention is to provide a method for improving skin condition, comprising the step of administering a liposome composition, comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant, to an individual in need thereof.

[0045] It is preferable that the above liposome composition is a cosmetic composition or a topical skin composition.

[0046] Specifically, the above 'improvement of skin condition' may mean one or more selected from the group consisting of skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening.

[0047] The above skin condition improvement may be one or more selected from the group consisting of skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening.

[0048]

[0049] A liposome composition according to one aspect or a cosmetic composition containing the same is characterized in that a melanocyte-targeting peptide can target target cells, including melanocytes, to increase the delivery efficiency of skin-active substances, and the stability and activity of the liposome are optimized according to the combination ratio of surfactants.

[0050]

[0051] Figure 1 shows the results of confirming the change in melanin production amount according to the liposome composition treatment of the example and comparative example.

[0052] Figure 2 shows the results of confirming the Tyrosinase inhibitory activity according to the liposome compositions of the examples and comparative examples.

[0053] Figure 3 shows the results of measuring the expression level of the whitening-related gene (TYR) according to the liposome composition treatment of the example and comparative example.

[0054] Figure 4 shows the results of measuring the expression level of a whitening-related gene (TRP1) according to the liposome composition treatment of the example and comparative example.

[0055]

[0056] The following examples will be explained in more detail. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0057]

[0058] Experimental Example 1: Liposome Preparation

[0059] Liposomes were prepared using the thin film method. Specifically, hydrogenated lecithin, which is required for liposome preparation, was dissolved in ethanol. Ethanol containing dissolved lipids was placed in a round-bottom flask, and a thin lipid film was prepared by completely evaporating and removing the solvent, ethanol, using a rotary evaporator.

[0060] Next, purified water and three types of melanocyte-specific melanocyte target peptides (NAP: Ac-Nle-DHfRWGK (Ac: Acetyl, f: D-Phenylalanine) (Sequence No. 1); LK-514: (4-phenylbutyryl)-Hf(tBu)-RK (Sequence No. 2); and γ-MSH: YVMGHFRWDRFK) (Sequence No. 3)), Polyglyceryl-6 laurate, Lauryl glucoside, Myristyl glucoside, Polyglyceryl-10 Caprylate, 1,2-hexanediol, Ethylhexylglycerin, and Ascorbic Acid were added to a flask and hydrated at room temperature. The melanocyte target peptides NAP, LK-514, and γ-MSH were mixed in a weight ratio of 1:1:1. The final prepared solution was used to form liposomes with a size of 100-150 nm using a high-pressure homogenizer (mMicrofludizer). The compositions of the prepared Examples and Comparative Examples 1 and 2 are shown in Table 1 below.

[0061]

[0062]

[0063] Experimental Example 2: Confirmation of whitening effect of liposome composition

[0064] 2-1. Checking Melanin Production Amount

[0065] To confirm the change in melanin production following treatment with the liposome composition, B16F0 cells were treated with 1X10 DMEM (no phenol) medium supplemented with 10% FBS. 5Cells were inoculated into a 6-well plate using cell / well. After stabilizing the cells for 24 hours, they were treated with α-melanocyte simulating hormone (α-MSH) and the compositions of Example and Comparative Examples 1 and 2 at various concentrations and cultured for 72 hours. After 72 hours of culture, the medium was removed and the cells were washed with PBS to obtain the cells. The cells were then treated with 200 µl of NaOH (1N NaOH + 10% DMSO) solution to dissolve the melanin at 60°C for 30 minutes, and the absorbance was measured at 475 nm using a microplate reader. The compositions of Example and Comparative Examples 1 and 2 prepared in Experimental Example 1 were treated at concentrations of 1% or 3%, respectively, and arbutin was treated at a concentration of 0.0025% as a positive control.

[0066] As a result, as shown in Figure 1, the liposome composition of the example was found to significantly reduce the amount of melanin produced in B16F0 cells compared to Comparative Examples 1 and 2, and the amount of melanin produced was found to decrease in a dependent manner of the treatment concentration of the composition of the example. From this, it was confirmed that the liposome composition of the example has excellent delivery efficiency of the active ingredient to target cells as it contains an appropriate amount of melanocyte-targeting peptide.

[0067]

[0068] 2-2. Confirmation of Tyrosinase Inhibitory Activity

[0069] To confirm the tyrosinase enzyme inhibitory activity following treatment with liposome compositions, 10 µl of tyrosinase from mushroom was reacted with 0.1 M sodium phosphate buffer (pH 6.5). Additionally, L-tyrosine and the compositions of Examples and Comparative Examples 1 and 2, diluted to their respective concentrations, were added and reacted for 5 minutes, after which the absorbance was measured at a wavelength of 490 nm using a microplate reader. As a positive control, 500 µg / ml of arbutin was treated.

[0070] As a result, as shown in Figure 2, the liposome composition of the example was found to significantly reduce the activity of Tyrosinase involved in melanin biosynthesis compared to Comparative Examples 1 and 2, and the Tyrosinase inhibitory activity was found to be high in a dependence on the treatment concentration of the composition of the example. From this, it was confirmed that the liposome composition of the example has excellent delivery efficiency of the active ingredient to target cells as it contains an appropriate amount of melanocyte-targeting peptide.

[0071]

[0072] 2-3. Confirmation of expression levels of whitening-related genes (TYR, TRP1)

[0073] To confirm the expression levels of whitening-related genes (TYR, TRP1) following treatment with liposome compositions, B16F0 cells were treated with 1X10 methyl ions in DMEM (no phenol) medium supplemented with 10% FBS. 5Cells were inoculated into a 6-well plate using a cell / well method. After stabilizing the cells for 24 hours, they were treated with α-melanocyte simulating hormone (α-MSH) and the compositions of Example 1 and Comparative Examples 1 and 2 prepared in Experimental Example 1 at concentrations of 1% or 3%, respectively, and cultured for 48 hours. Total RNA was extracted from the cultured cells using Trizol, and the expression levels of the TYR and TRP1 genes were confirmed through cDNA synthesis and Real-time PCR. Arbutin 200 μg / ml was treated as a positive control.

[0074] As a result, as shown in FIGS. 3 and 4, the liposome composition of the example was found to significantly reduce the expression levels of whitening-related genes TYR and TRP1 compared to Comparative Examples 1 and 2, and the expression levels of TYR and TRP1 were further reduced in dependence on the treatment concentration of the composition of the example. From this, it was confirmed that the liposome composition of the example has excellent delivery efficiency of the active ingredient to target cells as it contains an appropriate amount of melanocyte-targeting peptide.

[0075]

[0076] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

Claims

1. A liposome composition comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant.

2. A liposome composition according to claim 1, wherein the phospholipid is any one selected from the group consisting of lecithin, phosphatidylcholine, phosphatidic acid, phosphatidylserine, phosphatidyl glycerol, phosphatidylinositol, phosphatidylethanolamine, diphosphatidylglycerol, cardiolipin, plasmalogen, dicetylphosphate, distearoylphosphatidylcholine, dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylserine, eleostearoylphosphatidylcholine, eleostearoylphosphatidylethanolamine, eleostearoylphosphatidylserine, and combinations thereof.

3. A liposome composition according to paragraph 2, wherein the lecithin is hydrogenated lecithin.

4. A liposome composition according to claim 1, wherein the melanocyte target peptide is any one selected from the group consisting of NAP represented by the amino acid sequence of SEQ ID NO. 1, LK-514 represented by the amino acid sequence of SEQ ID NO. 2, γ-MSH represented by the amino acid sequence of SEQ ID NO. 3, and combinations thereof.

5. A liposome composition according to claim 4, wherein the melanocyte target peptide is included in an amount of 0.001 to 0.9 parts by weight per 100 parts by weight of the liposome composition.

6. A liposome composition according to claim 4, wherein the NAP, LK-514, and γ-MSH are included in a weight ratio of 0.5 to 5 : 0.5 to 5 : 0.5 to 5.

7. A liposome composition according to claim 1, wherein the surfactant is any one selected from the group consisting of polyglyceryl-6 laurate, lauryl glucoside, myristyl glucoside, polyglyceryl-10 caprylate, and combinations thereof.

8. A liposome composition according to claim 1, wherein the skin active substance is one or more compounds selected from the group consisting of vitamins or derivatives thereof, polyphenol compounds or flavonoid compounds, licorice extract, paper mulberry extract, bisabolol, glycyrrhizin, arbutin, phenethylenesorcinol, tranexamic acid, potassium methoxyhydrosalicylic acid, collagen, hyaluronic acid, and combinations thereof, or derivatives thereof.

9. The liposome composition of claim 1, wherein the liposome composition is for delivering a skin active substance to skin cells.

10. A cosmetic composition for improving skin condition comprising, as an active ingredient, a liposome composition of any one of claims 1 to 9.

11. A cosmetic composition for improving skin condition according to claim 10, wherein the skin condition improvement is one or more selected from the group consisting of skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening.

12. A topical skin composition for improving skin condition, comprising a liposome composition of any one of claims 1 to 9 as an active ingredient.

13. A method for improving skin condition comprising the step of administering a liposome composition, comprising an oil phase containing phospholipids; and an aqueous phase containing a skin active substance, a melanocyte target peptide, and a surfactant, to an individual in need thereof.

14. A method for improving skin condition according to claim 13, wherein the liposome composition is a cosmetic composition or a topical skin composition.

15. A method for improving skin condition according to claim 13, wherein the skin condition improvement is one or more selected from the group consisting of skin regeneration, anti-aging, antioxidant, wrinkle improvement, elasticity enhancement, and skin whitening.

Images